Iwanaga Yasuhiro, Sutherland David E R, Harmon James V, Papas Klearchos K
Transplantation Unit, Kyoto University Hospital, Kyoto, Japan.
Curr Opin Organ Transplant. 2008 Apr;13(2):135-41. doi: 10.1097/MOT.0b013e3282f63942.
To summarize advances and limitations in pancreas procurement and preservation for pancreas and islet transplantation, and review advances in islet protection and preservation.
Pancreases procured after cardiac death, with in-situ regional organ cooling, have been successfully used for islet transplantation. Colloid-free Celsior and histidine-tryptophan-ketoglutarate preservation solutions are comparable to University of Wisconsin solution when used for cold storage before pancreas transplantation. Colloid-free preservation solutions are inferior to University of Wisconsin solution for pancreas preservation prior to islet isolation and transplantation. Clinical reports on pancreas transplants suggest that the two-layer method may not offer significant benefits over cold storage with the University of Wisconsin solution: improved oxygenation may depend on the graft size; benefits in experimental models may not translate to human organs. Improvements in islet yield and quality occurred from pancreases treated with inhibitors of stress-induced apoptosis during procurement, storage, isolation or culture desirable before islet isolation and transplantation and may improve islet yield and quality. Methods for real-time, noninvasive assessment of pancreas quality during preservation have been implemented and objective islet-potency assays have been developed and validated. These innovations should contribute to objective evaluation and establishment of improved pancreas-preservation and islet-isolation strategies.
Cold storage may be adequate for preservation before pancreas transplants, but insufficient when pancreases are processed for islets or when expanded donors are used. Supplementation of cold-storage solutions with cytoprotective agents and perfusion may improve pancreas and islet transplant outcomes.
总结胰腺和胰岛移植中胰腺获取与保存的进展及局限性,并回顾胰岛保护与保存方面的进展。
心脏死亡后获取的胰腺,采用原位区域器官冷却,已成功用于胰岛移植。无胶体的Celsior溶液和组氨酸 - 色氨酸 - 酮戊二酸保存液在胰腺移植前用于冷藏时,与威斯康星大学溶液相当。在胰岛分离和移植前用于胰腺保存时,无胶体保存液不如威斯康星大学溶液。关于胰腺移植的临床报告表明,双层法可能并不比用威斯康星大学溶液冷藏有显著优势:改善氧合可能取决于移植物大小;实验模型中的益处可能无法转化到人体器官。在获取、储存、分离或培养过程中用应激诱导凋亡抑制剂处理胰腺,可提高胰岛产量和质量,这在胰岛分离和移植前是可取的,且可能改善胰岛产量和质量。已实施在保存期间实时、无创评估胰腺质量的方法,并开发和验证了客观的胰岛效能检测方法。这些创新应有助于客观评估并建立改进的胰腺保存和胰岛分离策略。
冷藏可能足以用于胰腺移植前的保存,但在将胰腺处理用于胰岛时或使用扩大标准供体时则不足。用细胞保护剂补充冷藏溶液并进行灌注可能改善胰腺和胰岛移植结果。